Australia markets close in 4 hours 8 minutes

AbCellera Biologics Inc. (ABCL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.4200-0.0100 (-0.29%)
At close: 04:00PM EDT
3.5000 +0.08 (+2.34%)
After hours: 07:52PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.04B
Enterprise value 410.66M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)28.56
Price/book (mrq)0.92
Enterprise value/revenue 11.48
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.44
52-week change 3-54.14%
S&P500 52-week change 321.45%
52-week high 38.0500
52-week low 33.3450
50-day moving average 33.9580
200-day moving average 34.6801

Share statistics

Avg vol (3-month) 31.29M
Avg vol (10-day) 31.49M
Shares outstanding 5294.05M
Implied shares outstanding 6301.77M
Float 8198.54M
% held by insiders 127.97%
% held by institutions 143.90%
Shares short (15 May 2024) 419.75M
Short ratio (15 May 2024) 414.25
Short % of float (15 May 2024) 48.73%
Short % of shares outstanding (15 May 2024) 46.72%
Shares short (prior month 15 Apr 2024) 423.09M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-551.48%

Management effectiveness

Return on assets (ttm)-9.59%
Return on equity (ttm)-12.56%

Income statement

Revenue (ttm)35.79M
Revenue per share (ttm)0.12
Quarterly revenue growth (yoy)-18.40%
Gross profit (ttm)N/A
EBITDA -203.5M
Net income avi to common (ttm)-146.9M
Diluted EPS (ttm)-0.5100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)698.02M
Total cash per share (mrq)2.37
Total debt (mrq)73.61M
Total debt/equity (mrq)6.52%
Current ratio (mrq)7.76
Book value per share (mrq)3.85

Cash flow statement

Operating cash flow (ttm)-41.52M
Levered free cash flow (ttm)-88.16M